Biodesix Announces Preliminary Fourth Quarter and Full‑Year 2025 Results (Unaudited)

Biodesix, Inc. (Nasdaq: BDSX), a diagnostics solutions company focused on lung disease, today released its preliminary, unaudited financial results for the fourth quarter and full fiscal year 2025. The company reported an estimated $28.8 million in revenue for Q4 2025, representing a 41% increase year‑over‑year, and $88.5 million in total revenue for the full year 2025, up 24% compared with 2024 — exceeding the top end of its prior guidance range of $84–$86 million. Biodesix’s Lung Diagnostics segment drove much of the growth, with estimated revenues of $25.2 million for Q4 and $79.2 million for the full year, increases of 47% and 22%, respectively, largely driven by higher test volumes and expanded reimbursement coverage. Estimated lung diagnostic test volumes reached 18,000 in Q4 and 62,600 for 2025, climbing 23% and 15% over the prior year. Development Services revenue also grew, with estimated increases of 13% in Q4 and 41% for the year. The company reaffirmed its expectation to achieve positive Adjusted EBITDA in Q4 2025 and reported $19.0 million in cash and cash equivalents as of December 31, 2025. Biodesix emphasized that these figures are preliminary and unaudited, subject to final audit adjustments. CEO Scott Hutton highlighted the company’s strong revenue performance, expanding clinical data support, and momentum heading into 2026. #Biodesix #Q42025 #LungDiagnostics #RevenueGrowth #SlimScan #GrowthStocks #CANSLIM